| 47 0.6 (1.29%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 55.81 | 1-year : | 65.19 |
| Resists | First : | 47.79 | Second : | 55.81 |
| Pivot price | 43.19  |
|||
| Supports | First : | 41.01 |
Second : | 36.81 |
| MAs | MA(5) : | 46.2 |
MA(20) : | 42.5 |
| MA(100) : | 44.61  |
MA(250) : | 51.61 |
|
| MACD | MACD : | 2 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 88.1 |
D(3) : | 86 |
| RSI | RSI(14): 77.6 |
|||
| 52-week | High : | 77.68 | Low : | 34.58 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NVO ] has closed below upper band by 15.0%. Bollinger Bands are 6.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 47.14 - 47.28 | 47.28 - 47.43 |
| Low: | 45.86 - 46.03 | 46.03 - 46.23 |
| Close: | 46.7 - 46.96 | 46.96 - 47.25 |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Tue, 12 May 2026
Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction - Benzinga
Tue, 12 May 2026
Novo Nordisk (NVO) Reports Strong Weight-Loss Results for Higher-Dose Wegovy - Yahoo
Tue, 12 May 2026
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock - Yahoo Finance
Tue, 12 May 2026
Novo posts trial data for higher-dose Wegovy (NVO:NYSE) - Seeking Alpha
Tue, 12 May 2026
NVO Stock Pops Premarket: Novo Nordisk Unveils Fresh Wegovy Data That Could Narrow Eli Lilly’s Obesity Lead - Stocktwits
Tue, 12 May 2026
Novo Nordisk stock price forecast: $47.90 resistance as NVO trades flat - Traders Union
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,360 (M) |
| Shares Float | 3,190 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 17,020 (K) |
| Shares Short P.Month | 24,700 (K) |
| EPS | 3.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.82 |
| Profit Margin | 33.1 % |
| Operating Margin | 44.5 % |
| Return on Assets (ttm) | 17.4 % |
| Return on Equity (ttm) | 60.7 % |
| Qtrly Rev. Growth | -7.6 % |
| Gross Profit (p.s.) | 75.8 |
| Sales Per Share | 91.98 |
| EBITDA (p.s.) | 45.62 |
| Qtrly Earnings Growth | -4.7 % |
| Operating Cash Flow | 119,100 (M) |
| Levered Free Cash Flow | 377 (M) |
| PE Ratio | 13.01 |
| PEG Ratio | 4.6 |
| Price to Book value | 6.88 |
| Price to Sales | 0.51 |
| Price to Cash Flow | 1.32 |
| Dividend | 1.26 |
| Forward Dividend | 0 |
| Dividend Yield | 2.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|